[144] GATX Corporation SEC Filing
Rhea-AI Filing Summary
GATX Corporation Form 144 notice reports a proposed sale of 979 shares of common stock through Charles Schwab (3000 Schwab Way, Westlake, TX). The filing lists an aggregate market value of $162,651 and shows 35,600,000 shares outstanding. The securities were acquired on 04/26/2025 as executive equity compensation, with payment recorded on the same date. The filer indicates no securities sold by the reporting person in the past three months. The approximate date of sale is listed as 08/22/2025 and the proposed transaction is to occur on the NYSE. The notice includes the required attestation about lack of undisclosed material information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale filing disclosing a small disposition of equity compensation; primarily a compliance disclosure.
The Form 144 documents a proposed sale of 979 common shares by a person who received those shares as executive compensation on 04/26/2025. The filing supplies broker details, an approximate sale date of 08/22/2025, and an aggregate market value of $162,651. Given the size of the proposed sale versus the reported 35.6 million shares outstanding, this appears to be a modest, routine disposition designed to meet regulatory disclosure requirements. The filing also confirms no other sales in the prior three months and includes the standard attestation regarding material nonpublic information.
TL;DR: Transparent disclosure of executive equity sale; no indications of unusual timing or material disclosure gaps.
The notice shows securities were acquired as equity compensation and are being offered for sale through a registered broker on the NYSE. The record that no other sales occurred in the past three months and the inclusion of the statutory attestation suggest adherence to Rule 144 procedures. The transaction size is small relative to outstanding shares, indicating limited potential market impact. The filing does not present information on any trading plan adoption or Rule 10b5-1 instructions.